Crosby Lori E, Walton Ashley, Shook Lisa M, Ware Russell E, Treadwell Marsha, Saving Kay L, Britto Maria, Peugh James, McTate Emily, Oyeku Suzette, Nwankwo Cara, Brinkman William B
Divisions of Behavioral Medicine.
Department of Pediatrics, University of Cincinnati College of Medicine.
J Pediatr Hematol Oncol. 2019 Jan;41(1):56-63. doi: 10.1097/MPH.0000000000001257.
National evidence-based guidelines recommend offering hydroxyurea to patients with sickle cell anemia 9 months of age and older using shared decision making, but offer no strategies to aid implementation. We developed a hydroxyurea multicomponent decision aid via a needs assessment, clinic observations, and iterative feedback to address parent decision needs and promote a discussion between clinicians and parents. A total of 75 parents and 28 clinicians participated across all phases. The decision aid was rated as useful. Hydroxyurea knowledge improved and decisional conflict decreased supporting the potential for use to facilitate shared decision making in pediatric sickle cell anemia.
国家循证指南建议，对于9个月及以上的镰状细胞贫血患者，应通过共同决策的方式提供羟基脲，但未提供有助于实施的策略。我们通过需求评估、临床观察和反复反馈，开发了一种羟基脲多成分决策辅助工具，以满足家长的决策需求，并促进临床医生与家长之间的讨论。在所有阶段，共有75名家长和28名临床医生参与。该决策辅助工具被评为有用。羟基脲知识有所提高，决策冲突有所减少，这支持了该工具在促进小儿镰状细胞贫血共同决策方面的应用潜力。
